大麻二酚治疗耐药性癫痫研究进展
Advances in the treatment of drug-resistant epilepsy with cannabidiol
王继芬 1叶兰 2冯占辉3
作者信息
- 1. 贵州医科大学附属医院神经内科,贵阳 550004;兴义市人民医院神经内科,兴义 562400
- 2. 贵州医科大学基础医学院,贵阳 550004
- 3. 贵州医科大学附属医院神经内科,贵阳 550004
- 折叠
摘要
全球约7 000万人罹患癫痫,在我国癫痫患者约1 000万例.癫痫的一线治疗方案为使用抗癫痫发作药物,尽管目前不断有抗癫痫药物获批上市,然而癫痫耐药患者人数仍占癫痫患者总人数的30％.大麻二酚(cannabidiol,CBD)是一种天然存在的具有抗癫痫特性的大麻素,临床研究结果表明CBD对Dravet综合征、Lennox Gastaut综合征、结节性硬化性癫痫等耐药性癫痫取得了良好的治疗效果,其作用机制广泛,安全性良好,已获得美国FDA批准上市.本文总结了耐药性癫痫发病机制和CBD治疗不同类型耐药性癫痫的疗效、机制和安全性,为临床进一步了解CBD提供参考.
Abstract
There are approximately 70 million people suffering from epilepsy around the world with about 10 million epilepsy patients in China.The main treatment of epilepsy is anti-seizure medicine.Despite the continuous development of these drugs,around 30％of epilepsy patients still experience drug resistance.Cannabidiol(CBD)is a natural cannabinoid that has been found anti-epileptic properties.Clinical studies have shown that CBD is effective in treating drug-resistant epilepsy,including conditions such as Dravet syndrome,Lennox Gastaut syndrome,and tuberous sclerosis epilepsy.CBD has a wide range of action mechanism and is considered safe,thus it has been approved by the US Food and Drug Administration.This article provides a summary of the pathogenesis of drug-resistant epilepsy,the efficacy,the mechanism,and safety of CBD in treating different types of drug-resistant epilepsy,aiming to provide epilepsy specialists with a reference to enhance their understanding of CBD.
关键词
癫痫/耐药性癫痫/大麻二酚/Dravet综合征/Lennox-Gastaut综合征/结节性硬化Key words
epilepsy/drug-resistant epilepsy/cannabidiol/Dravet syndrome/Lennox-Gastaut syndrom/tuberous sclerosing引用本文复制引用
基金项目
国家自然科学基金资助项目(81960224)
国家自然科学基金资助项目(82360266)
贵州省科技厅资助项目(黔科合基础-ZK[2023]一般395)
贵州省科技厅资助项目(黔科合基础-ZK[2023]一般324)
出版年
2024
NETL
NSTL
万方数据